Oxford Cannabinoid Technologies Holdings PLC, a pharmaceutical company based in Oxford, England, has announced the completion of its capital reorganisation. The company recently raised GBP646,000 by issuing 128.0 million new shares at a price of 0.5 pence each. Oxford Cannabinoid Technologies has stated that it will apply to the UK Financial Conduct Authority and the London Stock Exchange to admit these shares to the Main Market in London. Trading of the new shares is expected to commence next Tuesday. With the admission of the new shares, the total number of Oxford Cannabinoid shares in issue will be 1.09 billion.
The completion of the capital reorganisation marks an important milestone for Oxford Cannabinoid Technologies. This move allows the company to raise funds and pursue its goal of developing prescription cannabinoid medicines. The decision to seek admission of the new shares to the Main Market in London demonstrates the company’s confidence in the potential of its products and its commitment to providing investors with access to this emerging market.
In a statement, Oxford Cannabinoid Technologies highlighted the significance of this development for the company and its shareholders. The admission of the new shares to the Main Market will provide greater liquidity and visibility for the company’s stock, ultimately benefiting both existing and potential shareholders. The move also indicates the growing acceptance and interest in cannabinoid medicines, which hold promise for various medical applications.
Looking ahead, Oxford Cannabinoid Technologies aims to leverage its strengthened financial position to further advance its research and development efforts. The company is focused on utilizing the potential of cannabinoids to create effective and safe prescription medicines that address unmet medical needs. With the successful completion of the capital reorganisation, Oxford Cannabinoid Technologies is well-positioned to pursue its mission and contribute to the evolving landscape of pharmaceutical innovations.
As the global interest in cannabinoid medicines continues to grow, Oxford Cannabinoid Technologies’ progress in capital reorganisation serves as a testament to the company’s dedication to bringing novel solutions to patients. With the expected commencement of trading for the new shares next week, stakeholders and investors will be eagerly monitoring the company’s further developments and milestones.
Oxford Cannabinoid Technologies’ completion of its capital reorganisation represents a significant step forward for the company and the emerging field of prescription cannabinoid medicines. By expanding its financial capabilities and seeking admission of its new shares to the Main Market in London, the company is positioning itself for future growth and success. As the demand for innovative pharmaceutical solutions rises, Oxford Cannabinoid Technologies aims to make a lasting impact in this space.
